Home | GSK US
WEBHome | GSK US. Vaccines. People 50 and older are at increased risk for shingles – Protect your power. THRIVE@50+ empowers adults 50 years and older to learn about their risk for shingles.
GSK announces independent Consumer Healthcare company is …
WEBFeb 22, 2022 · GlaxoSmithKline plc (GSK) today announced that the new company, to result from the proposed demerger of Consumer Healthcare from GSK in mid-2022, will be called Haleon.
Update - GSK Consumer Healthcare
WEBJan 15, 2022 · Global leader in Consumer Healthcare. The Consumer Healthcare business has been transformed since 2014 through the successful integrations of GSK’s business with the Novartis consumer health portfolio in …
Products - GSK US
WEBProducts. Learn more about our product portfolio and how we're prioritizing vaccines and specialty medicines to get ahead of disease together. Below you can find the full A-Z list of our products available in the United States.
Consumer Healthcare Demerger - GSK
WEBOn Monday 18 July 2022, GSK plc (“GSK” or the “Company”) separated its Consumer Healthcare business from the GSK Group to form Haleon plc (“Haleon”), an independent listed company. The separation was effected by way of a demerger (the “Demerger”) of approximately 80% of GSK’s 68% holding in the Consumer Healthcare business to ...
Pfizer and GlaxoSmithKline Announce Joint Venture to Create a …
WEBPfizer Inc. (NYSE: PFE) and GlaxoSmithKline plc (NYSE:GSK) today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands.
GSK announces independent Consumer Healthcare company is …
WEBHaleon will be a new world-leader in consumer health with an exceptional portfolio of category-leading brands, including Sensodyne, Voltaren, Panadol and Centrum. Business is on track to demerge and list as a new company in mid-2022.
Update: Proposed demerger of the Consumer Healthcare business ... - GSK
WEBJun 1, 2022 · The proposed Demerger is the most significant corporate change for GSK in the last 20 years, creating two new leading companies, each with clear targets for growth and the ability to positively impact the health and lives of billions of people.
GSK spins off consumer health business worth up to $57 billion
WEBJan 15, 2022 · British drugmaker GSK will spin off its consumer health business Haleon worth up to an estimated 48 billion pounds ($57 billion) on Monday in the biggest listing in Europe in over a decade.
GlaxoSmithKline To Spin-Off Consumer Healthcare Business By ... - Forbes
WEBJul 15, 2021 · On June 23, 2021, GlaxoSmithKline plc (NYSE: GSK, $40.45, Market Cap: $101.8 billion) announced that it plans to spin-off its Consumer Healthcare division into a separately listed company. The...
Skip to content